Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Hysterical disorders in patients with hematological diseases].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025

Same author

[Therapy of mental disorders in patients with hematological malignancies].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2024

Same author

[Adherence to treatment of hematological malignancies patients with anxiety and depression].

Terapevticheskii arkhiv·2023

Same author

[Psychopharmacotherapy of mental disorders in hematological patients: security concerns].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2023

Same author

[Clinical and morphological characteristics of the atypical placentation spectrum in the uterus].

Arkhiv patologii·2023

Same author

[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].

Terapevticheskii arkhiv·2022

Search research articles

Related Experiment Video

Updated: May 6, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

[Eight-year experience in treating aggressive mediastinal large B-cell lymphomas].

Ia K Mangasarova, A U Magomedova, S K Kravchenko

Terapevticheskii Arkhiv

|October 22, 2013

Summary

This study differentiates diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMLBCL) in mediastinal lymph node involvement. The modified NHL-BFM-90 program shows varying efficacy for these distinct large B-cell lymphoma (LBCL) subtypes.

More Related Videos

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Related Experiment Videos

Last Updated: May 6, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Area of Science:

Hematology
Oncology
Pathology

Context:

Mediastinal lymph node involvement in large B-cell lymphoma (LBCL) presents diagnostic challenges.
Distinguishing between diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMLBCL) is crucial for treatment stratification.

Purpose:

To establish differential diagnostic criteria for DLBCL with primary mediastinal LN involvement versus PMLBCL.
To evaluate the efficacy of a modified NHL-BFM-90 (M-NHL-BFM-90) treatment program for these specific LBCL entities.

Summary:

The study analyzed 60 patients with LBCL primarily involving mediastinal lymph nodes.
Histological, phenotypic, and molecular analyses differentiated PMLBCL (39 patients) from DLBCL with primary mediastinal LN involvement (21 patients).
The M-NHL-BFM-90 protocol yielded high 5-year survival rates (95% for DLBCL, 86% for PMLBCL), with event-free survival at 95% and 78%, respectively. Pregnant patients with PMLBCL achieved remission with specific chemotherapy regimens.

Impact:

The findings highlight the heterogeneity of LBCL presenting with mediastinal lymph node involvement.
Treatment outcomes differ significantly between PMLBCL and DLBCL, despite similar initial presentations.
This research underscores the importance of accurate differential diagnosis for optimizing therapeutic strategies in mediastinal LBCL.